ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction
A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at…
All articles by Akosua Mireku
Akosua Mireku
@AkosuaMireku1
Akosua Mireku is a healthcare reporter for Pharmaceutical Technology. Akosua has a Bsc in medical physiology from the University of Manchester. She is particularly interested in topics in neuroscience, rare diseases, and global health equality
-
-
ESC 2024: Single-pill hypertension combo delivers positive results
Kicking off the second day of the European Society of Cardiology (ESC) Congress, researchers presented data suggesting that a single-pill…
-
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis
SGLT2 inhibitors show significant promise in the treatment of heart failure regardless of how long a patient has had type…
-
ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam
Alnylam Pharmaceuticals has shared detailed data further backing its rare disease drug Amvuttra (vutrisiran) from the Phase III trial Helios-B…
-
BioMarin lays off 225 employees in restructuring efforts
BioMarin Pharmaceuticals plans to let 225 staff members go as it reconfigures its Roctavian (valoctocogene roxaparvovec) development programme. The company…
-
AstraZeneca may pull plug on UK vaccine manufacturing plans
AstraZeneca is considering relocating its manufacturing facilities from the UK to the US, amidst potential cuts to state funding from…
-
South African president calls on WHO for better mpox response
Amidst the global health emergency declared for mpox, the South African president has called for a greater emphasis on an…
-
Clinical research in the UK must build on industry collaboration, says NIHR director
Last month, the Labour government came into power in the UK after almost two decades, with a plan to “kickstart…
-
US Government announces plan to reduce healthcare red tape
The Biden-Harris administration in the US has announced a new “Time is Money” initiative that aims to tackle “junk fees”…
-
Era of ADCs: Pharma companies innovate to stand out in a buzzing market
Antibody drug conjugates (ADCs) have taken over the cancer clinical research and dealmaking landscape, with new partnerships and agreements being…